Forum

Events

Partner Content

Last year we told you that the cell and gene industry would be worth $9 - $14 billion by 2026. We were wrong.

News

Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.